Table 3.
Associations Between Final Visual Acuity and Clinical Factors at Baseline and 12 Months after Initial Treatment.
| R | P value | |
|---|---|---|
| Baseline | ||
| Age | 0.566 | <0.001 |
| LogMAR visual acuity | 0.639 | <0.001 |
| Foveal thickness | 0.323 | 0.014 |
| Total NPA | 0.073 | 0.596 |
| Central macular NPA in the SCP | 0.199 | 0.376 |
| Central macular NPA in the DCP | 0.090 | 0.692 |
| 12 months after initial treatment | ||
| LogMAR visual acuity | 0.738 | <0.001 |
| Foveal thickness | 0.086 | 0.520 |
| Total NPA | 0.036 | 0.815 |
| Central macular NPA in the SCP | 0.306 | 0.055 |
| Central macular NPA in the DCP | 0.152 | 0.350 |
| Total number of IVR injections at 12 months | 0.009 | 0.944 |
IVR = intravitreal ranibizumab; LogMAR = logarithm of the minimum angle of resolution; NPA = retinal nonperfusion area. SCP = superficial capillary plexus; DCP = deep capillary plexus.